Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Arch Pharm (Weinheim) ; 357(1): e2300340, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-37880869

RESUMO

Drug repurposing is an emerging field in drug development that has provided many successful drugs. In the current study, paracetamol, a known antipyretic and analgesic agent, was chemically modified to generate paracetamol derivatives as anticancer and anticyclooxygenase-2 (COX-2) agents. Compound 11 bearing a fluoro group was the best cytotoxic candidate with half-maximal inhibitory concentration (IC50 ) values ranging from 1.51 to 6.31 µM and anti-COX-2 activity with IC50 = 0.29 µM, compared to the standard drugs, doxorubicin and celecoxib. The cell cycle and apoptosis studies revealed that compound 11 possesses the ability to induce cell cycle arrest in the S phase and apoptosis in colon Huh-7 cells. These results were strongly supported by docking studies, which showed strong interactions with the amino acids of the COX-2 protein, and in silico pharmacokinetic predictions were found to be favorable for these newly synthesized paracetamol derivatives. It can be concluded that compound 11 could block cell growth and proliferation by inhibiting the COX-2 enzyme in cancer therapy.


Assuntos
Antineoplásicos , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2/farmacologia , Inibidores de Ciclo-Oxigenase 2/química , Acetaminofen/farmacologia , Relação Estrutura-Atividade , Ciclo-Oxigenase 2/metabolismo , Linhagem Celular Tumoral , Ensaios de Seleção de Medicamentos Antitumorais , Antineoplásicos/química , Proliferação de Células , Simulação de Acoplamento Molecular , Estrutura Molecular
2.
Molecules ; 27(20)2022 Oct 14.
Artigo em Inglês | MEDLINE | ID: mdl-36296495

RESUMO

In the current study, new benzimidazole-based 1,3,4-oxadiazole derivatives have been synthesized and characterized by NMR, IR, MS, and elemental analysis. The final compounds were screened for cytotoxicity against MDA-MB-231, SKOV3, and A549 cell lines and EGFR for inhibitory activities. Compounds 10 and 13 were found to be the most active against all the tested cell lines, comparable to doxorubicin, and exhibited significant inhibition on EGFR kinase, with IC50 0.33 and 0.38 µM, respectively, comparable to erlotinib (IC50 0.39 µM). Furthermore, these two compounds effectively suppressed cell cycle progression and induced cell apoptosis in MDA-MB-231, SKOV3, and A549 cell lines. The docking studies revealed that these compounds showed interactions similar to erlotinib at the EGFR site. It can be concluded that the synthesized molecules effectively inhibit EGFR, can arrest the cell cycle, and may trigger apoptosis and therefore, could be used as lead molecules in the development of new anticancer agents targeting EGFR kinase.


Assuntos
Antineoplásicos , Inibidores de Proteínas Quinases , Ensaios de Seleção de Medicamentos Antitumorais , Cloridrato de Erlotinib/farmacologia , Inibidores de Proteínas Quinases/química , Receptores ErbB/metabolismo , Antineoplásicos/química , Linhagem Celular Tumoral , Simulação de Acoplamento Molecular , Proliferação de Células , Apoptose , Pontos de Checagem do Ciclo Celular , Benzimidazóis/farmacologia , Doxorrubicina/farmacologia , Relação Estrutura-Atividade
3.
Nanomaterials (Basel) ; 11(11)2021 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-34835556

RESUMO

This investigation aimed at evaluating the efficiency of micro and nanoclays as a low-cost material for the removal of crystal violet (CV) dye from an aqueous solution. The impacts of various factors (contact time, pH, adsorbent dosage, temperature, initial dye concentration) on the adsorption process have been taken into consideration. Six micro and nanoclay samples were obtained by treating clay materials collected from different locations in the Albaha region, Saudi Arabia. Out of the six tested micro and nanoclays materials, two (NCQ1 and NCQ3) were selected based on the highest adsorption efficiency for complete experimentation. The morphology and structure of the selected micro and nanoclay adsorbents were characterized by various techniques: SEM-EDX, FTIR, XRF, XRD, and ICP-MS. The XRF showed that the main oxides of both nanoclays were SiO2, Al2O3, Fe2O3, K2O, CaO, and MgO, and the rest were impurities. All the parameters affecting the adsorption of CV dye were optimized in a batch system, and the optimized working conditions were an equilibrium time of 120 min, a dose of 30 mg, a temperature of 25 °C, and an initial CV concentration of 400 mg/L. The equilibrium data were tested using nonlinear isotherm and kinetic models, which showed that the Freundlich isotherm and pseudo-second-order kinetics gave the best fit with the experimental data, indicating a physico-chemical interaction occurred between the CV dye and both selected micro and nanoclay surfaces. The maximum adsorption capacities of NCQ1 and NCQ3 adsorbents were 206.73 and 203.66 mg/g, respectively, at 25 °C. The thermodynamic factors revealed that the CV dye adsorption of both micro and nanoclays was spontaneous and showed an exothermic process. Therefore, the examined natural micro and nanoclays adsorbents are promising effective adsorbents for the elimination of CV dye from an aqueous environment.

4.
Pharmaceuticals (Basel) ; 14(9)2021 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-34577570

RESUMO

A library of novel naproxen based 1,3,4-oxadiazole derivatives (8-16 and 19-26) has been synthesized and screened for cytotoxicity as EGFR inhibitors. Among the synthesized hybrids, compound2-(4-((5-((S)-1-(2-methoxynaphthalen-6-yl)ethyl)-1,3,4-oxadiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)phenol(15) was the most potent compound against MCF-7 and HepG2cancer cells with IC50 of 2.13 and 1.63 µg/mL, respectively, and was equipotent to doxorubicin (IC50 1.62 µg/mL) towards HepG2. Furthermore, compound 15 inhibited EGFR kinase with IC50 0.41 µM compared to standard drug Erlotinib (IC50 0.30 µM). The active compound induces a high percentage of necrosis towards MCF-7, HePG2 and HCT 116 cells. The docking studies, DFT and MEP also supported the biological data. These results demonstrated that these synthesized naproxen hybrids have EGFR inhibition effects and can be used as leads for cancer therapy.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa